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Histone deacetylase 6 (HDAC6), a member of the HDAC family whose major substrate is α-tubulin, has become a target for drug
development to treat cancer due to its major contribution in oncogenic cell transformation. Overexpression of HDAC6 correlates
withtumorigenesisandimprovedsurvival;therefore,HDAC6maybeusedasamarkerforprognosis.Previousworkdemonstrated
that in multiple myeloma cells, inhibition of HDAC6 results in apoptosis. Furthermore, HDAC6 is required for the activation
of heat-shock factor 1 (HSF1), an activator of heat-shock protein encoding genes (HSPs) and CYLD, a cylindromatosis tumor
suppressor gene. HDAC6 contributes to cancer metastasis since its upregulation increases cell motility in breast cancer MCF-7
cells and its interaction with cortactin regulates motility. HDAC6 also aﬀects transcription and translation by regulating the heat-
shock protein 90 (Hsp90) and stress granules (SGs), respectively. This review will discuss the role of HDAC6 in the pathogenesis
and treatment of cancer.
1.Introduction
Inhibition of histone deacetylation has become an accepted
target for cancer therapy [1–4]. Cancer, the second leading
cause of death in the United States [5], involves the
uncontrolled growth of abnormal cells that can spread
to other areas of the body [6]. It is generally treated
with chemotherapy, such as vincristine, vinblastine, and
colchicine bind tubulin and inhibit microtubule (MT)
polymerization, which block mitosis. Taxol, on the other
hand, stabilizes the MT and blocks cell division [7]. Despite
chemotherapy, many patients relapse and die from cancer.
The American Cancer Society estimated 565,650 deaths this
year [5]; therefore, new targets for cancer therapy need to be
investigated.
Histone deacetylases (HDACs) are primarily involved in
the deacetylation of histones [8, 9] but some HDACs, such as
HDAC6 can also aﬀect the function cytoplasmic nonhistone
proteins. This review will discuss the interaction of HDAC6
with these nonhistone proteins, and discuss how HDAC6 is
a key regulator of many signaling pathways that are linked to
cancer, thereby making HDAC6 an attractive target.
HDACs are grouped into three classes based on their
p r i m a r yh o m o l o g yt ot h r e eSaccharomyces cerevisiae HDACs
[10,11].TheclassIHDACs,whichincludeHDAC1,HDAC2,
HDAC3, and HDAC8, are most related to the yeast tran-
scriptional regulator yRPD3. Class II HDACs, which include
HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10,
share domains similar to yHDA1. HDAC11 is most closely
related to class I HDACs; however, no classiﬁcation has been
givensinceitssequencesimilarityistoolow.ClassIIIHDACs
are similar to the NAD+-dependent ySIR2 [10, 11].
The deacetylase-trichostatin A (TSA) and deacetylase-
suberoylanilide hydroxamic acid (SAHA) crystal structures
of a homologue from the bacterium Aquifex aeolicus revealed
the histone acetylase catalytic core and established a general2 Journal of Biomedicine and Biotechnology
mechanism for HDAC inhibition [12]. TSA and SAHA are
two types of HDACs inhibitors that have antitumor eﬀects
since they can inhibit cell growth and induce terminal
diﬀerentiation [12]. The conserved catalytic domain of
HDAC involves about 390 amino acids, forming a tube-like
shape pocket with a wider bottom [12]. Removal of an acetyl
group from substrate occurs through a “charge-relay system”
consisting of two adjacent histidine residues, two aspartic
residues,andonetyrosineresidueatthebottomofthepocket
[12]. A Zn
2+ cation binds near the bottom of the pocket
and it is coordinated by two additional aspartates and one
histidine and also by a water molecule; in general, HDAC
inhibitors function by chelating the zinc ion, making the
charge-relay system dysfunctional [12].
HDAC6 is a unique member of class II because it
contains two homologous catalytic domains [8, 13]. Both
catalytic domains of HDAC6 are fully functional HDACs
and contribute independently to the overall activity of the
HDAC6 protein, (see [8, 14–17]F i g u r e1 ) .I no n es t u d y ,
bothHDAC6catalyticdomainswererequiredforfulltubulin
deacetylase (TDAC) activity [18, 19]; however, in other
studies the TDAC activity was attributed to the second
domain [20–22]. HDAC6, like all other HDACs, is inhibited
by TSA; however, HDAC6 is uniquely resistant to the potent
HDAC inhibitors trapoxin-B and sodium butyrate. These
drugs were used to show that HDAC6 is a deacetylase for α-
tubulin in vivo,a n din vitro [20, 23]. HDAC6 was found not
to interact with histones,i nv i v o ,h o w e v e r ,in vitro,H D A C 6
is able to deacetylate histones [8]. This result led to the
investigation of an HDAC inhibitor that mediates acetylation
of proteins other than histones. An HDAC6 inhibitor,
known as tubacin (Tubulin acetylation inducer), was isolated
through a multidimensional chemical genetic screen of 7,392
small molecules and cell-based assay targeting acetylation
activity of proteins other than histones [21, 24]. Unlike other
histone deacetylase inhibitors, tubacin was found to inhibit
the deacetylation of α-tubulin in mammalian cells without
aﬀecting the level of histone acetylation, gene-expression, or
cell cycle progression [21, 24].
The HDAC6 gene is localized in Xp11.23 (http://www
.ncbi.nlm.nih.gov/) and was ﬁrst cloned by two diﬀerent
groups Grozinger et al. [8]a n dV e r d e la n dK h o c h b i n[ 13].
It is the largest protein yet identiﬁed in humans with 1,216
amino acids [8]. Most HDACs are located in the nucleus;
however, class II HDACs, are able to translocate to the
cytoplasm [10]. HDAC6 predominates in the cytoplasm due
to the NES and the SE14 motifs [10, 14], (Figure 1). HDAC6
is also found on the perinuclear and leading-edge subcellular
regions,associatedwithp150glued-containingmotorcomplex
[23]. It contains a unique ubiquitin-binding zinc-ﬁnger
domain (ZnF-UBP domain, also known as the PAZ, BUZ or
DAUP domain) in its C-terminal region [25] and a dynein-
binding domain (DBD) [7]( Figure 1). Other HDACs such
as HDAC10 or a spliced variant of HDAC9 can be localized
both in the nucleus and cytoplasm, and HDAC11, which
localizes in the nucleus, has been reported to coprecipitate
with HDAC6 in the cytoplasm [10]. The expression levels of
HDAC6wereobservedintheheart,liver,kidney,testis,brain,
and, pancreas [8, 13].
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Cytoplasmic
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Figure 1: HDAC6 functional domains. The only HDAC with
two tandem catalytic domains, deacetylase domains (DD1 and
DD2). Tubulin, Hsp90, and cortactin have been found to be
HDAC6 substrates. The nuclear export signal (NES) prevents
accumulation of the protein in the nucleus and the Ser-Glu-
containing tetrapeptide (SE14) region ensures a stable anchorage of
the enzyme in the cytoplasm. The linker between both DDs is able
to bind dynein and the high aﬃnity ubiquitin-binding zinc ﬁnger
domain (ZnF-UBP).
2. HDAC6ExpressionandCancer
Expression proﬁling analysis, with cDNA microarray in
MCF-7 cells, showed that the HDAC6 gene is an estrogen-
regulated gene [26]. Estrogens play an important role in
t h en o r m a lg r o w t ho fm a m m a r yg l a n d s ,a sw e l la si n
the development of estrogen-dependent breast cancer [27].
The estrogen receptor α (ERα) status of breast cancer
patients is widely used as an indicator for endocrine therapy
responsiveness and for prognosis, but 30–40% of the ERα
positivepatientsdonotrespondtothetherapy,and10%who
are ERα negative do respond [3, 27].
The estrogen-mediated up-regulation of HDAC6 sug-
gests that there might be a link between the levels of HDAC6
expression and metastasis of breast cancer that could be
useful in the prognosis of patients. One study involving
quantitative real-time reverse transcription-PCR, as well as
immunohistochemistry in 135 female patients with invasive
breast cancer showed that higher levels of expression of
HDAC6 mRNA correlated with tumor size (less than 2cm),
low histologic grade, and ERα and progesterone receptor-
positive tumors [27] .T h eh i g hl e v e lo fH D A C 6m R N A
expression also correlated with better prognosis in terms
of disease-free survival and better response to endocrine
treatment. In a diﬀerent study, the expression levels of
HDAC6 were evaluated by immunohistochemical staining of
139 consecutively archived human breast cancer tissues [3].
In this study, a subset group of ER-positive patients with
higher levels of HDAC6 expression who received adjuvant
treatment with tamoxifen (TAM), a selective estrogen recep-
tor modulator, resulted in improved survival. These results
suggest that HDAC6 could potentially serve as an additional
marker for prognosis in breast cancer patients.
The overexpression of HDAC6 has been identiﬁed in a
variety of other cancer cell lines and mouse tumor models.
The expression levels of HDAC6 in ovarian cancer cells and
tissues were higher in low-grade and high-grade ovarian
carcinomas compared with benign lesions and immortalized
ovariansurfaceepitheliumcelllines[28].HDAC6expression
was also investigated in retrovirus expressing SV40 early
region or/and RasG12V transformed and nontransformedJournal of Biomedicine and Biotechnology 3
human embryonic kidney cells (HEK), prostate epithelial
cells (PrEC), and mouse embryonic ﬁbroblast (MEF) cells
and it was found that oncogenic Ras can lead to up-
regulation of HDAC6 [29]. HDAC6 expression was also up-
regulated in primary oral squamous cell lines and its level
of expression correlated with primary tumor stage [30]. In
ad i ﬀerent study, HDAC6 was consistently overexpressed in
primary acute myeloid leukemia (AML) blasts and in some
myeloblastic cell lines [31]. The up-regulation of HDAC6 in
diverse tumors and cell lines suggests an important role in
cancer and it is therefore being widely investigated.
3.HDAC6IsRequiredfor Oncogenic
Cell Transformation
As t u d yp e r f o r m e db yL e ee ta l .[ 29] found that HDAC6 is
required for eﬃcient oncogenic tumorigenesis by providing
anchorage-independent proliferation to transduced cells.
MEFs derived from wild type HDAC6-null embryos and
transduced with retrovirus expressing SV40 early region and
RasG12V resulted in >10-fold fewer colonies in the HDAC6-
null oncogenic transduced MEFs samples than in the wild
type oncogenic transduced MEFs. These results strongly
indicated that HDAC6 is required for Ras-induced onco-
genic transformation by providing anchorage-independent
proliferation, a hallmark of malignant transformation.
Anchorage-independent proliferation allows the cells to
survive by escaping anoikis, a type of cell death due to
lack of suﬃcient cell adhesion to the surrounding basement
membrane and extracellular matrix (ECM) [29].
HDAC6 is required to maintain the transformed pheno-
types of a number of established oncogenic cell lines and for
tumor growth. Knockdown of HDAC6 in SKOV3 ovarian
cancer, SKBR3 breast carcinoma, and MCF7 breast cancer
cell lines inhibited the anchorage-independent growth of
those cancer cells by 5-fold to 30-fold [29]. This sug-
gests that HDAC6 plays a major role in the survival
of tumor cells. To test whether HDAC6 was critical
for tumorigenesis, immunocompromised severe combined
immunodeﬁcient (SCID)-Beige mice were subcutaneously
injected with either HDAC-6 speciﬁc shRNA or scrambled
control and it was found that the growth of HDAC6
knockdown cells was signiﬁcantly retarded [29]. Further-
more, HDAC6 knockdown cells reconstituted with wild
type HDAC6, but not with catalytically inactive mutant
HDAC6, regained its phenotype, indicating that HDAC6 is
speciﬁcally required for tumorigenic growth. Further studies
of the role of HDAC6 and tumorigenesis were performed
using 7,12-dimethylbenzanthracene (DMBA) and 12-O-
tetradecanoylphorbor-13-acetate (TPA) carcinogen-induced
spontaneous tumorigenesis [29]. After tumor induction, the
tumors decreased by half and the formation of tumors
was retarded by two weeks in the HDAC6 null mice.
These results suggested that HDAC6 is required for optimal
tumor growth. RAS/MAPK signaling pathway is known to
be required for tumorigenesis, and this study also showed
that HDAC6 plays a major role in this pathway. HDAC6
knockout mice demonstrated reduced phosphorylation of
AKT and ERK1/2, signaling pathways involved in tumor
growth, and lower levels of activated Ras than those derived
from wild-type mice. Thus, HDAC6 is considered to be
required for the eﬃcient activation of the oncogenic Ras
signaling pathway. These results indicate that HDAC6 is a
major contributor of tumorigenesis and maintenance of the
transformed phenotype.
4. HDAC6InhibitionandCYLDActivationLead
toaDelayintheCellCycle
In a diﬀerent study of HDAC6 and its role in tumori-
genesis, it was found that CYLD-mediated inhibition of
HDAC6 was essential for CYLD activation and delay in
the cell cycle. CYLD is a tumor-suppressor gene present
in patients suﬀering from cylindromatosis, a benign skin
tumor [32]. In CYLD-transduced melanoma cells, as well
as other tumor cell lines, CYLD constitutively colocalizes
with acetylated MTs in the perinuclear region, where as in
primary mouse keratinocytes melanoma cells or primary
human melanocytes, CYLD perinuclear localization occurs
after TPA treatment or exposure to UV light [30]. In this
study, it was found that keratinocytes and melanoma cells
thatweretreatedwithTSAortubacinyieldedincreasedlevels
of acetylated tubulin in enhanced green ﬂuorescent protein
(EGFP)-tagged expressing melanoma cells, while treatment
of EGFP-CYLD-expressing melanoma cells with TSA or
tubacin failed to increase acetylated ∝-tubulin. These results
indicatedthatCYLDendogenouslyinducesacetylationof ∝-
tubulin by inhibiting HDAC6. Furthermore, it was found
that inhibition of HDAC6 by the N-terminal cytoskeleton-
associated protein-glycine-conserved (CAP-GLY) domains
of CYLD mediated inhibition of HDAC6 [32].
CYLD-mediated HDAC6 inhibition was observed to
enhance its association with the MTs, reduce the rate of
cytokinesis, and delay cell cycle (Figure 2). Inhibition of
BCL-3, a proto-oncogene, by the deubiquitinase activity of
CYLD is mediated by an additional signal induced by TPA
a n dr e q u i r e si n t a c ta c e t y l a t e dM T s[ 32]. CYLD-mediated
inhibition of HDAC6 results in perinuclear translocation
of CYLD, and this in turn mediates BCL-3 inhibition by
blocking its nuclear translocation. The lack of BCL-3 in
the nucleus inhibits the transcriptional activity of NF-κB
p50/p52, reduces the expression of cyclin-D1, and delays
G1/S transition of the cell cycle [32]( Figure 2). These studies
demonstrated how inhibition of HDAC6 can prevent tumor
growth, indicating that HDAC6 should be considered as a
major target in transformed cells.
5. The Role of HDAC6duringCellular Stress
Response and Tumorigenesis
A defense mechanism known to counteract the toxic
eﬀects of misfolded protein accumulation is carried out
by the proteasome and the aggresome pathway; this in
turn gives a survival advantage to transformed cells. A
puriﬁed HDAC6-containing complex from mouse testis
cytosolic extracts revealed the presence of vasolin-containing4 Journal of Biomedicine and Biotechnology
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Figure 2: CYLD-mediated inhibition of HDAC6 leads to a delay in the cell cycle. CYLD binds acetylated microtubules and inhibits HDAC6.
Inhibition of HDAC6 leads to increased levels of acetylated ∝-tubulin and this induces more binding of CYLD to MTs. CYLD binds BCL-3,
and in the presence of TPA blocks its nuclear translocation, thereby inhibiting cyclin-D1.
protein/protein 97 (VCP/p97) and phospholipase A2-
activating protein/ubiquitin fusion degradation protein 3
(PLAP/UFD3), two proteins that are known to control
protein ubiquitination [25]. HDAC6 contains a ZnF-UBP
domain and a dynein-binding domain (Figure 1). These
ﬁndings led to the hypothesis that HDAC6 participates in
cargo sorting and transport by regulating the acetylation of
MTs and by binding ubiquitinated proteins; therefore, the
eﬀect of HDAC6 on MTs and its role in protein degradation
in response to cell stress are widely being investigated.
6. MicrotubuleStabilization Leads to
IncreasedLevelsof HDAC6-Mediated
Acetylated α-Tubulin
MTs play a role in cell cycle division (mitotic spindle),
intracellular protein traﬃcking, shape maintenance, cell
motility and attachment, and in signal transduction [44],
hence, they are validated targets for anticancer therapy
[45]. MTs are components of the cytoskeleton and they
are composed of the tubulin molecule, αβ tubulin dimer
(Mr ∼ 100,000), which polymerizes to form 13 linear
protoﬁlaments with a rigid hollow rod of approximately
25nm in diameter and several microns in length [7, 46]. The
MTs also bind proteins that are collectively known as the MT
associated proteins (MAPs). In animal cells, the major MT
organizing center (MTOC) is the centrosome [7, 46]. The
MTs undergo rapid cycles of assembly and disassembly and
it has been established that their instability arises from the
hydrolysis of GTP bound to β-tubulin during or shortly after
polymerization [7]. Cytoplasmic MTs, which polymerize
and depolymerize at high rates, in the presence of taxol,
an antimitotic drug, bind the drug and are stabilized. This
MT assembly allows for acetylation of α-tubulin to occur
[20, 23, 47]. Therefore, the reversible acetylation on the ε-
amino group of Lys40 near the N-terminus of α-tubulin is
coupled to MT turnover [47].
HDAC6 plays a role in regulating the stability of dynamic
MTs [18, 20, 23]. It was observed that in vivo,d e p o l y m e r i z e d
tubulin is rapidly deacetylated while tubulin acetylation
g e n e r a l l yo c c u r so ns t a b l eo rp o l y m e r i z e dM T s[ 18, 20,
23]. Furthermore, a group of researchers reported that
combination of farnesyl transferase inhibitor lonafarnib and
taxol enhance HDAC6-dependent tubulin deacetylation in
breast and cell lung carcinoma cells [2].
7. HDAC6anditsRole inthe Aggresome
Pathway inResponsetoCellularStress
Targeting the proteasome or the aggresome to induce
apoptosis or programmed cell death is one of the methods to
target cancer cells. Transformed cells accumulate more mis-
foldedproteins,whicharedisposedofbytheproteasomeand
the aggresome [33, 48, 49]; therefore, cancer cells are more
dependent on the proteasome and aggresome activity than
nonmalignant cells for cell survival [33]. Upon inhibition
of the proteasome, the high binding aﬃnity of HDAC6 to
ubiquitinated proteins activates the aggresome pathway [14]
(Figure 3). Misfolded proteins form particulate (∼200nm)
miniaggregates [36]. HDAC6 binds the ubiquitinated pro-
teins and delivers them to the motor protein dynein, which
it turn, transports the cargo along the MTs to the MTOC,
where intermediate ﬁlament cytoskeleton surrounds the
particle to form an aggresome [33, 36]. The aggresome
is dynamic and it recruits chaperones and proteasomes
[36]. Once this occurs, it activates the autophagic clearance
and the autophagosomes fuse to lysosomes resulting in the
degradation of the misfolded proteins [50]. The HDAC6Journal of Biomedicine and Biotechnology 5
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Figure 3: Cell stress response: activation of the aggresome pathway, HSPs, and transcriptional response. (a) Under nonstress conditions,
protein degradation occurs through the proteasome. HDAC6 is sequestered by VCP/p97 and forms a basal complex with HSF1 and HSP90.
This keeps HSF1 in its inactive form. (b) Inhibition of the proteasome leads to an increase of misfolded proteins. HDAC6 binds these
ubiquitinated protein aggregates and the basal complex disassembles. This complex dissociation activates HSF1, which eventually activates
HSPs. The protein aggregates are transported along the MTs to MTOC to form an aggresome and autophagic clearance is activated. HDAC6
can also modulate Hsp90 acetylation levels and aﬀect the maturation of client proteins, such as the glucocorticoid and androgen receptors,
impairing gene transcription activation.
partner VCP/p97 is a chaperone with segregase activity. It
disassembles the ubiquitinated aggregate/HDAC6 complex
by extracting or sequestering HDAC6, so that the ubiqui-
tinated proteins can be degraded through the proteasome
instead of the aggresome [14, 36].
To study the eﬀects of HDAC6 inhibition on the stress
response, the HDAC6 inhibitor, tubacin, was used to test
its eﬀect on multiple myeloma cells. Tubacin-mediated
α-tubulin acetylation disrupted HDAC6-dynein complex
and synergistically increased the bortezomib-induced apop-
totic eﬀect in myeloma cells by c-Jun NH2-terminal
kinase/caspase activation [37]. Multiple myeloma is cancer
of plasma cells and can become resistant to conventional
chemotherapy. The combination of bortezomib and tubacin
was able to inhibit the proliferation of myeloma cells in vitro.
[37]. More importantly, it was found that tubacin did not
have an eﬀect on normal peripheral blood mononuclear cells
[37], hence the inhibition of HDAC6 by tubacin may be used
for combined chemotherapy to treat myeloma or other types
of cancer.
In ovarian cancer cells, their elevated metabolic activity
results in increased ubiquitin proteasome-system (UPS)
stress and this in turn, leads to an up-regulation of HDAC6
expression [28]. In one study, ovarian cancer cells were6 Journal of Biomedicine and Biotechnology
treated with HDAC6-speciﬁc inhibitors, tubacin and its
derivative NK84. The treatment signiﬁcantly inhibited the
growth/survival of the ovarian cancer cell lines relative to
the immortalized ovarian surface epithelial (IOSE) cell lines.
Combined inhibition of both the proteasome and HDAC6-
mediated aggresome degradation pathways is targeted with
PS-341 and NK84, respectively, and the results showed
synergistic cell death induced by both drugs. Furthermore,
immunoﬂuorescence analysis of the polyubiquitinated pro-
teins in ovarian cancer cells, treated with both PS-341
and NK84 drugs, showed that HDAC6 inhibition prevented
aggresome formation [28].
8. HDAC6 Is Required for Activation of
HSF1andHeat-Shock ProteinEncoding
GenesResponse
An elegant study performed by Boyault et al. [34] using
primary cells and established cell lines isolated from
HDAC6-deﬁcient mice, or human HDAC-6 deﬁcient cells
re-expressing wild type or mutated HDAC6, found that
VCP/p97 is recruited by HDAC6 to a heat-shock protein
90/heat-shock factor 1 (Hsp90/HSF1) complex to form a
“basal complex” in unstressed cells (Figure 3). At baseline,
Hsp90 maintains HSF1 in its inactive form. HSF1 is a
transcription factor that is essential in the activation of HSPs
inresponsetotheaccumulationofmisfoldedproteinscaused
by heat shock or proteasome inhibition [29, 34]( Figure 3).
The HSP response helps to reduce protein aggregate toxicity
by increasing the expression of major cellular chaperones
that either disaggregate proteins and help in their normal
refolding or deliver them to the proteasome [35, 51]. Upon
proteasome inhibition, HDAC6 binds the ubiquitinated
aggregates and dissociation of HDAC6 and Hsp90 from
HSF1 occurs. In the absence of VCP/p97, the Hsp90/HSF1
complex remains; therefore, the VCP/p97 ATPase activity
seems to play a role in the dissociation of the Hsp90/HSF1
complex [34].
The essential role of HDAC6 in the activation of HSF1
is in accordance with the ﬁndings that similar to HDAC6-
deﬁcient cells and HDAC6-null mice, HSF-1-null MEFs were
found to suppress skin tumor formation induced by DMBA-
TPA treatment and oncogenic Ras-mediated anchorage-
independent proliferation [29, 35]. Both HSF1 and HDAC6
regulate the oncogenic RAS/MAPK signaling pathway, and
their presence is required for maintenance of transformed
phenotypes in established tumor cells [29, 35].
9. HDAC6-MediatedTransportation of Stress
GranulesLeads to Reversible Translational
Suppressionin Response to Cellular Stress
HDAC6 also plays an essential role in a diﬀerent cellular
response induced by environmental stress. Kwon et al. [43]
found that either of the two HDAC6 domains is suﬃcient to
interact with cytoplasmic stress granule (SG) components,
which are involved in reversible translational suppression in
response to cellular environmental stress. The deacetylase
activity and the ubiquitin-binding function of HDAC6 were
found to be essential in the formation of SGs [43]. HDAC6
recruits the SGs to motor protein via binding of another
SG protein, Ras-GTPase-activating protein SH3 domain-
binding protein 1 (G3BP1) to allow SGs movement along the
MTs. SGs are also ubiquitin positive and this allows direct
binding to HDAC6 and MTs. In this study, disruption of
MTs or motor proteins was found to inhibit individual SG
components along the MTs. This type of HDAC6-mediated
stress response strongly suggested a role of HDAC6 in the
control of RNA metabolism and translation. It is worth
mentioning that in a diﬀerent study using cultured HSF-1
deﬁcient MEFs under growth factor-depleted conditions or
serum starvation, reduced levels of three ribosomal subunits,
L26RP, L28RP, and S6RP, as well as those of phosphorylated
ribosomal protein S6 kinase (p70 S6K), were observed
[35]. p70 S6K is known to be a regulator of translational
activity [35]. These results suggest that HSF1, which is
activated by HDAC6, plays a role in ribosome biogenesis
and protein translation, pathways that contribute to cancer
[35].
10.HDAC6ModulatesCellMotility
Cell motility plays a key role in tumor metastasis; hence,
ﬁbroblast motility has been used as a model to study the
mechanisms of tumor cell migration in vivo [52]. Motile
ﬁbroblast contains two diﬀerent types of MTs: The highly
dynamic MTs predominate randomly throughout the cell
periphery, and the less dynamic ones are found between the
ﬁbroblast nucleus and its leading edge [53]. In ﬁbroblast
crawling, actin is a key player, however, the MTs also play
importantroles,sinceMTsarerequiredfortheestablishment
and maintenance of cell polarity and directional movement
[52]. Fibroblasts were observed to require dynamic MTs
for the remodeling and turnover of their focal adhesions
[54]. The detachment from the extracellular matrix can
slow down invasion migration, so adhesion turnover is rate-
limiting for rapid migration of ﬁbroblasts [55]. Nevertheless,
dependence for cell polarity on MT dynamism is seen only
in some cell types; for example, ﬁbroblasts and epithelial
cells, which require an intact MT cytoskeleton to migrate
during wound healing [56]. Faster migrating cells, such as
leukocytes, do not require an intact MT cell cytoskeleton
[56].
Studies of cell motility revealed that overexpression of
HDAC6 increases chemotactic cell motility, suggesting that
deacetylation of at least one cytoplasmic HDAC protein
enhances motility [23]. HDAC inhibitors, such as TSA and
SAHA block invasive cell motility by altering gene expression
as a result of hyperacetylated HDAC nuclear substrates, such
as histones or transcription factors [38]. Studies have shown
that, as expected, tubacin leads to a reduction in cell motility
[21, 38]. The inhibition of HDAC6 by tubacin, which
leads to the hyperacetylation of tubulin, blocks ﬁbroblast
invasion motility similarly to the inhibition of all HDACs
by TSA [38]. It was observed that in HDAC6-inhibited cells,
MT dynamics is decreased, leading to an increase of focal
adhesion accumulation, thus a decrease in ﬁbroblast motilityJournal of Biomedicine and Biotechnology 7
Table 1: Overview of HDAC and its role in cancer.
Tumorigenesis
HDAC6 expression and its mediated HSF1 activation are essential for tumor growth and maintenance of
oncogenic phenotype by promoting anchorage-independent proliferation to transformed cells [3, 26–35].
CYLD-mediated HDAC6 inhibition leads to delay in the cell cycle and reduced rate of cytokinesis [30, 32].
Cell survival
HDAC6 binds ubiquitinated protein aggregates and this leads to the dissociation of the basal complex,
and eventual activation of the aggresome pathway [28, 33, 36].
HDAC6 inhibition leads to apoptosis [37].
Cell motility or metastasis
HDAC6 overexpression leads to increased cell motility [3, 21, 28, 38].
HDAC6 inhibition leads to hyperacetylated cortactin and impaired cell motility [15, 17].
HDAC6 inhibition also leads to its impaired catalytic domain aﬀecting MT dynamism [39].
Transcriptional response HDAC6 deacetylates Hsp90 and prevents the maturation of glucocorticoid and androgen receptors
[40–42].
Translational response HDAC6 forms a complex with SGs and G3BP1 and eventually induces a reversible translational
suppression [43].
[38]. Another group performed a scratch assay and trans-
Matrigel migration assays and showed that NK84-mediated
inhibition of HDAC6, in ovarian cancer cell lines retarded
spreading and inhibited migration, respectively [28].
In a diﬀerent study, treatment of ERα positive breast
cancer MCF-7 cells with estradiol or stably transfected
with HDAC6 revealed that HDAC6 is a novel estrogen
up-regulated gene and its expression led to increased cell
motility [3]. Saji et al. [3] also found that either TAM, the
pure antiestrogen ICI 182,780, or tubacin, prevented the
estradiol-induced HDAC6 accumulation and deacetylation
of α-tubulin, leading to reduced motility.
HDAC6 can also interact with a diﬀerent substrate,
cortactin, in vivo and in vitro, and both HDAC6 catalytic
domains are necessary for interaction [17], (Figure 1).
Cortactin is an acetylated protein found at areas of dynamic
actin assembly, such as the leading edge of migrating cells
[17]. This protein is originally known as a substrate of Src
tyrosine kinase and it plays a role in regulating cell motility
[57, 58]. Cortactin has been found to be overexpressed in
several carcinomas [58]. It interacts with F-actin to promote
polymerization and branching by modulating a “charge
patch” in the cortactin repeat region [15]. Zhang et al. [15]
found that inhibition of HDAC6 leads to hyperacetylation of
cortactin and prevents its translocation to the cell periphery,
blocks association with F-actin, and impairs cell motility.
In a diﬀerent study, HDAC6 was found to play an
important role in the chemotaxis of T-lymphocytes, inde-
pendent of its deacetylase activity. The knockdown of
HDAC6 expression in T-cells decreased their chemotactic
capability; however, HDAC6 inhibitors, such as TSA and
tubacin, showed that the deacetylase activity of HDAC6
was not involved in the modulatory eﬀect of HDAC6
on cell migration [59]. Cabrero et al. [59] suggested hat
HDAC6 might act as an on/oﬀ switch, regulating the rapid
formation(10to20foldsfasterthanﬁbroblasts)ofmolecular
complexes required for lymphocyte migration. In favor of
that hypothesis the results of two studies were mentioned.
First, HDAC6 reversibly complexes with phosphatases such
as protein phosphatase 1 (PP1) and upon HDAC inhibition,
release of PP1 from its complex with HDAC6 leads to
the dephosphorylation of Akt, which in turn aﬀects cell
migration. The second ﬁnding was that tubulin acetylation
decreases with inhibition of RhoA activity and since Rho
GTPases coordinate both poles of migrating T-lymphocytes
and control the dynamics of actin and tubulin cytoskeleton,
HDAC6 may act as a mediator between actin- and tubulin-
associated proteins to regulate motility [59].
A recent study involving the eﬀect of HDAC6 on MT
found that the impaired catalytic domain of HDAC6 is
responsible for MT dynamics. In two diﬀerent studies using
NIH 3T3 ﬁbroblast or A549 cells, it was found that MT
stabilization is not promoted by tubulin acetylation [21, 60].
Palazzo et al. [60] reported that reduced motility is a conse-
quence of alterations in the degree of tubulin acetylation and
notofMTstabilization.Zilbermanetal.[39]showedthatthe
impaired catalytic domain of HDAC6, induced by HDAC6
inhibitors, TSA or tubacin, or point mutations in either of
the two catalytic domains, is responsible for the regulation of
MT dynamics, rather than tubulin acetylation alone. In this
study,HDAC6knockdownincreasedtubulinacetylation,but
had no eﬀect on the MT growth velocity, in the presence or
absence of tubacin.
11. HDAC6Modulates the Acetylation Statusof
Hsp90 andRepresses Transcription
HDAC6 was also shown to have a third substrate, heat shock
protein 90 (Hsp90), and aﬀect transcriptional activation
(Figure 3). Hsp90 functions by facilitating the structural
maturation and complex formation of client proteins,
including steroid hormone receptors and selected kinases
[40, 41]. HDAC6 was found to regulate the activity of
Hsp90. Inactivation or knockdown of HDAC6 led to Hsp90
hyperacetylation,itsdissociationfromcochaperonep23,and
lossofchaperoneactivity.ThelossofHsp90activityprevents
the maturation ofthe glucocorticoidreceptor (GR),aﬀecting
ligand binding, nuclear translocation, and transcriptional
activation [40, 42]. In a diﬀerent study, knockdown of
HDAC6 in prostate cancer (PCa) C4-2 cells led to the
hyperacetylation of Hsp90, impaired ligand-independent
nuclear localization of endogenous androgen receptor (AR),
inhibited prostate-speciﬁc antigen (PSA) expression, and cell8 Journal of Biomedicine and Biotechnology
growth in the absence or presence of dihydrotestosterone
(DHT) [41]. These ﬁndings suggest that HDAC6 potentially
aﬀects the activity of other client proteins by regulating
Hsp90. Nevertheless, other studies have shown that HDAC6
is related to cell migration rather than to transcriptional
regulation [21, 23].
12. Conclusions
HDAC6 should be considered a target for cancer therapy due
to its essential role in many signaling pathways that provide
an advantage to malignant cells to survive and maintain its
phenotype(Table 1).HD A C6aswellasitssubstrateHSF1are
essential for eﬃcient oncogenic transformation by support-
ing anchorage-independent proliferation to prevent anoikis.
HDAC6 and HSF1 can also regulate oncogenic Ras/MAPK
signaling pathways, which are required for eﬃcient tumor
growth. High levels of HDAC6 expression were found to
correlate with tumorigenesis, and ERα positive breast cancer
patients who received adjuvant treatment with TAM showed
better survival prognosis. Thus, HDAC6 could potentially
be used as an additional marker for prognosis. HDAC6 is
required for the activation of HSF1, a master activator of
HSPs, leading to massive expression of chaperones; thereby,
contributing to oncogenic transformed cell survival. HDAC6
isinvolvedintheactivationofSGsleadingtoreversibletrans-
lational suppression, thus, helping transformed cells survive
cellular environmental stress. HDAC6 can also regulate other
proteins such as Hsp90, leading to the inhibition of steroid
receptors activity and transcriptional activation.
Studies of HDAC6 and its role in cell motility suggest
its participation in cancer metastases and migration. The
impaired catalytic domain of HDAC6 was found to be
responsible for the regulation of MT dynamics. Recent
studies have also shown that the inhibition of HDAC6 by
tubacinleadstotheaccumulationofmisfoldedubiquitinated
proteins and apoptosis in multiple myeloma cells. The
eﬀects of HDAC6 on protein degradation and apoptosis
revealed that this protein participates in cargo sorting and
transportbyregulatingtheacetylationofMTsandbindingto
ubiquitinated proteins. It is possible that the same HDAC6-
mediated protective eﬀect in response to cellular stress
is observed in other cells; therefore, more studies using
diﬀerentcancercelllinesshouldbeperformed.Furthermore,
sinceinhibitionofHDAC6stabilizestheMTs,otherpotential
apoptotic pathways that inhibit oncogenic tumorigenesis
need to be investigated.
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